Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vincerx Pharma, Inc.LSAC · Entity 84409 | Director · Chief Operating Officer · 10% owner | March 05, 2020 | March 09, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vincerx Pharma, Inc.
Report date March 05, 2020 · Filed March 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy way of LifeSci Investments, LLC | 1,701,000 |
Reported balance
Holding disclosure · report date 2020-03-05 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,701,000 F1: Mr. Rice is a managing member of LifeSci Investments, LLC. He disclaims any pecuniary interest in the securities except to the extent of his ownership interest in LifeSci Investments, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Rice is a managing member of LifeSci Investments, LLC. He disclaims any pecuniary interest in the securities except to the extent of his ownership interest in LifeSci Investments, LLC.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 30, 2023 · Filed November 01, 2023
Section 16 reporting ended · disclosed 2023-11-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 347,085 |
Reported balance
After 2023-10-30 transaction · row 1
1 source rowRow 1 · 2023-10-30 · Sale · Disposed 72,603 · Balance 347,085 F1: The sale reported herein was made pursuant to Rule 10b5-1 (c) trading plans adopted by the reporting person effective as of 03-25-2020, 02-08-21, 02-24-2022, and 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported herein was made pursuant to Rule 10b5-1 (c) trading plans adopted by the reporting person effective as of 03-25-2020, 02-08-21, 02-24-2022, and 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 15, 2020 Filed Apr 16, 2020 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 18,750 | $2.06 | $38,625.00 |
DisclosureSEC source: 0001437749-20-007796 · rdgdoc.xml · nonDerivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2020 Filed Apr 16, 2020 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 18,750 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-20-007796 · rdgdoc.xml · derivative · entry 5 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,750 Underlying: Common Stock · 18,750 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2020 Filed Apr 16, 2020 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 18,750 | $9.03 | $169,312.50 |
DisclosureSEC source: 0001437749-20-007796 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,739 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of May 15, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.94 to $9.30, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 13, 2020 Filed Apr 16, 2020 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 18,750 | $2.06 | $38,625.00 |
DisclosureSEC source: 0001437749-20-007796 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 25, 2020 Filed Mar 28, 2020 01:58 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantRestricted Stock Award · Derivative | 34,641 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-20-006395 · rdgdoc.xml · derivative · entry 5 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,641 Underlying: Common Stock · 34,641 shares Expires not disclosed F5 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 125% of the reported number of shares in column 5 based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. This restricted stock was granted in lieu of such reporting person receiving a 2020 cash performance bonus. F5 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 125% of the reported number of shares in column 5 based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. This restricted stock was granted in lieu of such reporting person receiving a 2020 cash performance bonus. Read SEC document |
| March 25, 2020 Filed Mar 28, 2020 01:58 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantRestricted Stock Award · Derivative | 28,868 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-20-006395 · rdgdoc.xml · derivative · entry 4 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,868 Underlying: Common Stock · 28,868 shares Expires not disclosed F4 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2021 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F4 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2021 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| March 25, 2020 Filed Mar 28, 2020 01:58 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 28,868 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-20-006395 · rdgdoc.xml · nonDerivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,739 F3 · security: The restricted stock was granted pursuant to the Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2020 compensation. F3 · price: The restricted stock was granted pursuant to the Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2020 compensation. Read SEC document |
| March 25, 2020 Filed Mar 28, 2020 01:58 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 7,056 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-20-006395 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,871 F2 · security: The restricted stock was granted pursuant to the Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2020 compensation. F2 · price: The restricted stock was granted pursuant to the Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2020 compensation. Read SEC document |
| March 25, 2020 Filed Mar 28, 2020 01:58 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 12,991 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-20-006395 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,815 F1 · security: The restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") and vests in full on September 25, 2020. This restricted stock was granted to the reporting person in lieu of such reporting person's 2019 cash performance bonus. F1 · price: The restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") and vests in full on September 25, 2020. This restricted stock was granted to the reporting person in lieu of such reporting person's 2019 cash performance bonus. Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 01:25 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 18,750 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-20-005027 · rdgdoc.xml · derivative · entry 6 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,500 Underlying: Common Stock · 18,750 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 01:25 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 18,750 | $8.44 | $158,250.00 |
DisclosureSEC source: 0001437749-20-005027 · rdgdoc.xml · nonDerivative · entry 4 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,824 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.42 to $9.71, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 01:25 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 18,750 | $2.06 | $38,625.00 |
DisclosureSEC source: 0001437749-20-005027 · rdgdoc.xml · nonDerivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,574 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 01:25 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 18,750 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-20-005027 · rdgdoc.xml · derivative · entry 5 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,250 Underlying: Common Stock · 18,750 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 01:25 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 18,750 | $12.16 | $228,000.00 |
DisclosureSEC source: 0001437749-20-005027 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,824 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.99 to $13.00, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 01:25 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 18,750 | $2.06 | $38,625.00 |
DisclosureSEC source: 0001437749-20-005027 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,574 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 01:12 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 2,190 | $15.02 | $32,893.80 |
DisclosureSEC source: 0001437749-20-004025 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,824 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 02:36 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 18,750 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-20-002652 · rdgdoc.xml · derivative · entry 6 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 18,750 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 02:36 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 18,750 | $14.17 | $265,687.50 |
DisclosureSEC source: 0001437749-20-002652 · rdgdoc.xml · nonDerivative · entry 4 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,014 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.12 to $14.19, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 02:36 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 18,750 | $2.06 | $38,625.00 |
DisclosureSEC source: 0001437749-20-002652 · rdgdoc.xml · nonDerivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2020 Filed Feb 14, 2020 02:36 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 18,750 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-20-002652 · rdgdoc.xml · derivative · entry 5 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,750 Underlying: Common Stock · 18,750 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2020 Filed Feb 14, 2020 02:36 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 18,750 | $13.69 | $256,687.50 |
DisclosureSEC source: 0001437749-20-002652 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,014 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.59 to $13.72, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 11, 2020 Filed Feb 14, 2020 02:36 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 18,750 | $2.06 | $38,625.00 |
DisclosureSEC source: 0001437749-20-002652 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2020 Filed Jan 17, 2020 01:35 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 18,750 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-20-000755 · rdgdoc.xml · derivative · entry 6 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,500 Underlying: Common Stock · 18,750 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2020 Filed Jan 17, 2020 01:35 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 18,750 | $15.79 | $296,062.50 |
DisclosureSEC source: 0001437749-20-000755 · rdgdoc.xml · nonDerivative · entry 4 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,014 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.72 to $15.85, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 16, 2020 Filed Jan 17, 2020 01:35 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 18,750 | $2.06 | $38,625.00 |
DisclosureSEC source: 0001437749-20-000755 · rdgdoc.xml · nonDerivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 14, 2020 Filed Jan 17, 2020 01:35 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 18,750 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-20-000755 · rdgdoc.xml · derivative · entry 5 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,250 Underlying: Common Stock · 18,750 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 14, 2020 Filed Jan 17, 2020 01:35 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 18,750 | $15.91 | $298,312.50 |
DisclosureSEC source: 0001437749-20-000755 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,014 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.75 to $16.04, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 14, 2020 Filed Jan 17, 2020 01:35 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 18,750 | $2.06 | $38,625.00 |
DisclosureSEC source: 0001437749-20-000755 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 01:27 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,247 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001437749-19-024347 · rdgdoc.xml · derivative · entry 7 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,247 shares Expires 2021-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: The reporting person's Form 4 filed on November 14, 2019 reported a remainder of 10,247 derivative securities when in fact the remainder was 20,247 derivative securities beneficially owned by the reporting person. Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 01:27 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,247 | $15.11 | $154,832.17 |
DisclosureSEC source: 0001437749-19-024347 · rdgdoc.xml · nonDerivative · entry 5 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,014 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.99 to $15.18, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 01:27 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,247 | $1.12 | $11,476.64 |
DisclosureSEC source: 0001437749-19-024347 · rdgdoc.xml · nonDerivative · entry 4 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,261 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2019 Filed Dec 13, 2019 01:27 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001437749-19-024347 · rdgdoc.xml · derivative · entry 6 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,247 Underlying: Common Stock · 10,000 shares Expires 2021-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: The reporting person's Form 4 filed on November 14, 2019 reported a remainder of 10,247 derivative securities when in fact the remainder was 20,247 derivative securities beneficially owned by the reporting person. Read SEC document |
| December 10, 2019 Filed Dec 13, 2019 01:27 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $15.37 | $153,700.00 |
DisclosureSEC source: 0001437749-19-024347 · rdgdoc.xml · nonDerivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,014 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.35 to $15.41, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 10, 2019 Filed Dec 13, 2019 01:27 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.12 | $11,200.00 |
DisclosureSEC source: 0001437749-19-024347 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2019 Filed Dec 13, 2019 01:27 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GiftCommon Stock | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-024347 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,014 F1 · kind: This transaction represents a charitable donation to a third party. No value was received for the gifted shares. Read SEC document |
| November 14, 2019 Filed Nov 15, 2019 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001437749-19-022979 · rdgdoc.xml · derivative · entry 6 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,247 Underlying: Common Stock · 10,000 shares Expires 2021-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2019 Filed Nov 15, 2019 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $13.98 | $139,800.00 |
DisclosureSEC source: 0001437749-19-022979 · rdgdoc.xml · nonDerivative · entry 4 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,014 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.78 to $14.19, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 14, 2019 Filed Nov 15, 2019 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.12 | $11,200.00 |
DisclosureSEC source: 0001437749-19-022979 · rdgdoc.xml · nonDerivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2019 Filed Nov 15, 2019 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001437749-19-022979 · rdgdoc.xml · derivative · entry 5 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,247 Underlying: Common Stock · 10,000 shares Expires 2021-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2019 Filed Nov 15, 2019 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $16.78 | $167,800.00 |
DisclosureSEC source: 0001437749-19-022979 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,014 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.69 to $16.83, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 12, 2019 Filed Nov 15, 2019 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.12 | $11,200.00 |
DisclosureSEC source: 0001437749-19-022979 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 17, 2019 Filed Oct 18, 2019 01:14 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001437749-19-020228 · rdgdoc.xml · derivative · entry 6 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,247 Underlying: Common Stock · 10,000 shares Expires 2021-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 17, 2019 Filed Oct 18, 2019 01:14 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $16.26 | $162,600.00 |
DisclosureSEC source: 0001437749-19-020228 · rdgdoc.xml · nonDerivative · entry 4 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,014 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.14 to $16.42, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 17, 2019 Filed Oct 18, 2019 01:14 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.12 | $11,200.00 |
DisclosureSEC source: 0001437749-19-020228 · rdgdoc.xml · nonDerivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 15, 2019 Filed Oct 18, 2019 01:14 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001437749-19-020228 · rdgdoc.xml · derivative · entry 5 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,247 Underlying: Common Stock · 10,000 shares Expires 2021-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 15, 2019 Filed Oct 18, 2019 01:14 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $15.93 | $159,300.00 |
DisclosureSEC source: 0001437749-19-020228 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,014 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.83 to $16.07, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 15, 2019 Filed Oct 18, 2019 01:14 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.12 | $11,200.00 |
DisclosureSEC source: 0001437749-19-020228 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 11, 2019 Filed Sep 12, 2019 00:11 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 14,571 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001437749-19-018247 · rdgdoc.xml · derivative · entry 6 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,571 shares Expires 2021-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option vested as of the last day of the calendar quarter in which the Company first achieved cash flow break even after the grant date. Read SEC document |
| September 11, 2019 Filed Sep 12, 2019 00:11 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 14,571 | $19.36 | $282,094.56 |
DisclosureSEC source: 0001437749-19-018247 · rdgdoc.xml · nonDerivative · entry 4 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,014 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.30 to $19.41, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 11, 2019 Filed Sep 12, 2019 00:11 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 14,571 | $1.12 | $16,334.09 |
DisclosureSEC source: 0001437749-19-018247 · rdgdoc.xml · nonDerivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,585 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.